March 26 (Reuters) - Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental drug met the main goal in a late-stage study in patients with ...

Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs ...

Wave Life Sciences shares plunged over 55% on Thursday after a higher dose of its experimental ​obesity drug failed to show a ...

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...

Anavex Life Sciences (AVXL) stock crashed on March 25 after the company unexpectedly withdrew its marketing authorization ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...

Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

In life sciences, enterprise value only emerges when generative AI is treated as a business capability and embedded into ...

Add Yahoo as a preferred source to see more of our stories on Google. South Korea–based biotech firm 3billion plans to open a 13,000-square-foot AI-driven genetic testing lab in North Austin, a ...

Achieve exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H ...

In a glimmer of hope for one of the most battered sectors of commercial real estate, the vacancy rate for U.S. life sciences space went down for the first time in three years at the end of 2025. At ...